Decera Clinical Education Oncology Podcast

Afleveringen

• 
  Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma 30.09.2026 28min

  In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.
• 
  ASCO 2026 Updates in Metastatic Breast Cancer 22.09.2026 18min

  In this podcast, experts review practice-informing data presented at the ASCO 2026 annual conference that may reshape treatment decisions in metastatic breast cancer. The discussion examines ctDNA-guided treatment adaptation for emergent ESR1 mutations in HR-positive/HER2-negative disease, emerging endocrine-based precision strategies targeting ER and PI3K/AKT signaling, and first-line TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer. The experts place the SERENA-6, ELEVATE, PIKALO-1, ASCENT-04, ASCENT-03, and TROPION-Breast02 findings in clinical context and how the results, including biomarker testing, immunotherapy eligibility, sequencing, safety, and the maturity of the evidence are influencing their clinical practice.
• 
  Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape 10.09.2026 35min

  The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Listen to this podcast with 2 experts discussing current gaps and clinical needs for patients with relapsed ES-SCLC, the scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC, the expanding role of antibody–drug conjugates (ADCs) and T-cell engagers in ES-SCLC including recent efficacy and safety data for B7-H3–directed ADCs such as ifinatamab deruxtecan (I-DXd) in ES-SCLC and the strengths and limitations of the available evidence. The experts synthesize this information along with their clinical experiences to illustrate how they are individualizing the care of patients with ES-SCLC based on patient-specific characteristics that influence the selection and sequencing of treatment with a case-based discussion. They close with a reminder of the importance of discussing ongoing trials of investigational B7-H3–directed ADCs and other therapies in ES-SCLC with the goal of continuing to improve outcomes for patients with this disease.
• 
  Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing 04.09.2026 29min

  In this podcast episode, experts discuss the scientific rationale and emerging clinical evidence for targeting CDH6 in platinum-resistant ovarian cancer, with a focus on CDH6-directed antibody–drug conjugates (ADCs) such as raludotatug deruxtecan and other investigational agents. The discussion examines CDH6 expression in ovarian tumors, the current limitations of biomarker testing and patient selection, and how ADC characteristics, including target expression, payload, linker properties, and drug-to-antibody ratio, may influence efficacy. Experts also review early clinical activity and key toxicities associated with CDH6-directed ADCs, including cytopenias, gastrointestinal adverse events, fatigue, and interstitial lung disease, and emphasize monitoring and supportive care considerations. The conversation further explores unresolved questions about ADC sequencing, potential cross-resistance between agents sharing topoisomerase I inhibitor payloads, changes in tumor biomarker expression over time, and the potential role of repeat biopsy in guiding treatment selection as additional targeted therapies become available.
• 
  ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer 04.09.2026 9min

  In this podcast, experts review 2 of the most important studies presented at the ASCO 2026 annual conference that inform treatment decisions for patients with early-stage hormone receptor–positive/HER2-negative breast cancer. The discussion focuses on the phase III OPTIMA trial, which evaluated Prosigna PAM50-guided chemotherapy selection and the potential for chemotherapy de-escalation in selected patients, with stimulating insights on the role of ovarian function suppression with endocrine therapy in premenopausal women. Their discussion also examines the NATALEE PAM50 biomarker analysis, which demonstrated benefit from adjuvant ribociclib across intrinsic molecular breast cancer subtypes without a significant treatment-by-subtype interaction. Together, these findings help clarify how genomic risk assessment, menopausal status, tumor biology, and adjuvant CDK4/6 inhibitor therapy may be integrated into individualized treatment planning and shared decision-making.
• 
  CELMoDs on the Horizon: A New Chapter in Lymphoma Care 24.08.2026 22min

  In this podcast, 2 experts explore the evolving role of CELMoD-based strategies in lymphoma, with a focus on the biologic mechanisms and emerging clinical evidence for golcadomide in diffuse large B-cell lymphoma and follicular lymphoma. Listeners will hear how CELMoDs differ from established immunomodulatory and immune-based therapies, review evidence from ongoing and early-phase studies of golcadomide as monotherapy and in combination regimens, and consider practice-relevant issues including efficacy, toxicity, treatment sequencing, combination strategies, and the experts’ thoughts on how emerging CELMoD therapy can be adopted into community-based lymphoma care.
• 
  Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma 20.08.2026 13min

  Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss health disparities and equitable care strategies in multiple myeloma, including treatment for underserved populations and keys for everyday practice.
• 
  Experts Discuss CELMoD Agents for Multiple Myeloma 20.08.2026 26min

  Listen to expert faculty as they discuss the use of CELMoD agents to manage multiple myeloma, including a recent approval, mechanism of action and differentiation from IMiDs, current data, and potential treatment settings.
• 
  Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer 14.08.2026 32min

  Oral targeted therapies are increasingly used across early-stage and metastatic HR-positive/HER2-negative breast cancer, but optimal use can be complicated by disease setting, biomarker results, prior therapy, tolerability concerns, and adherence needs. In this podcast, expert faculty discuss current evidence and practical strategies for selecting and sequencing oral targeted therapies, applying biomarker-informed decision-making, monitoring and managing adverse events, and using pharmacist-led approaches to support adherence and long-term treatment persistence.
• 
  TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care 13.08.2026 36min

  Tenosynovial giant cell tumor (TGCT) can present significant diagnostic and management challenges, particularly in patients with diffuse disease where symptoms, functional limitations, and risk of recurrence may substantially affect quality of life. In this podcast, expert faculty discuss the evolving TGCT treatment landscape, including the biologic rationale for targeting the CSF1/CSF1R pathway, the role of imaging and multidisciplinary care, patient-centered treatment goals, and practical considerations for integrating surgery and systemic therapies into individualized management strategies.
• 
  Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives 12.08.2026 28min

  This podcast examines evidence guiding the use of anti-CD38–based therapy in smoldering and newly diagnosed multiple myeloma, including risk stratification, transplant eligibility, frailty, and measurable residual disease assessments. Pharmacists review findings from pivotal trials of daratumumab- and isatuximab-containing regimens, discuss triplet and quadruplet treatment strategies for transplant-eligible and transplant-ineligible patients, and consider the evolving roles of transplantation, maintenance therapy, and response-adapted care. The discussion also addresses pharmacist-led supportive care, toxicity prevention and management, dose modification, and subcutaneous anti-CD38 administration to support individualized treatment selection and safe, sustained therapy.
• 
  New and Emerging Targeted Therapies for Patients With DLBCL 07.08.2026 38min

  The management of patients with DLBCL is rapidly changing with several targeted agents across different drug classes on the near horizon. Experts discuss the potential utility of surovatamig, a novel bispecific antibody targeting CD19 and CD3 in overcoming resistance to CD20-targeted therapies, and the potential roles of golcadomide, a first-in-class oral CELMoD, and tafasitamab plus lenalidomide and R-CHOP in untreated DLBCL. They also discuss ongoing trials of other bispecific antibodies and acalabrutinib, a BTK inhibitor, in DLBCL. Listen to this podcast with 2 experts from Europe and the United States discussing the unmet clinical needs in DLBCL, the expanding role of approved targeted therapies, challenges with access to these new therapies in different regions, important ongoing clinical trials of new and novel agents in DLBCL that are poised to change practice, and key presentations and results in DLBCL reported at the recent 2026 European Hematology Association Congress in Sweden.
• 
  Changing the Paradigm in HER2-Positive Early Breast Cancer 07.08.2026 25min

  The DESTINY-Breast11 and DESTINY-Breast05 trials of trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer, but the broad new indications leave questions about sequencing and patient choice. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings.
• 
  Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma 03.08.2026 17min

  Listen to this podcast to hear Sagar Lonial, MD, FACP, FASCO, and Mohamad Mohty, MD, PhD, discuss recent advances, future directions, and the integration of novel protein degradation modulator-based therapy into myeloma care, including what clinicians may expect when incorporating these therapies into practice.
• 
  To Treat or Not to Treat: Assessing Risk and Treatment Options in High-Risk SMM 29.07.2026 48min

  The care of patients diagnosed with smoldering multiple myeloma (SMM) continues to evolve with the rapid release of new clinical evidence. Listen to this podcast with 2 experts discussing what healthcare professionals need to know about risk stratification, how to interpret evidence for early intervention, and how to decide between treatment and observation in an individualized manner. They will also discuss optimal treatment selection and sequencing considerations, proactive and mitigation approaches to ensure treatment safety, supportive care measures, optimization of shared decision-making and patient communication, and emerging therapies and key ongoing clinical trials for patients with high-risk SMM.
• 
  Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC 28.07.2026 22min

  For patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy, treatment selection remains challenging because of aggressive disease biology, high symptom burden, limited survival expectations, and variable access to emerging therapies across Europe. This podcast examines European expert perspectives on the evolving role of TROP-2–directed antibody–drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, with attention to treatment sequencing, reimbursement barriers to recent approvals, toxicity-informed treatment selection, ocular and pulmonary toxicity monitoring, and care team readiness for implementing ADC-based therapy in routine practice.
• 
  Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM 23.07.2026 30min

  Bispecific antibody therapy continues to rapidly change the care of patients with relapsed/refractory multiple myeloma (RRMM). In this podcast, learners will hear 2 oncology specialty pharmacists discuss recent evidence-based information and updated safe-use guidelines and implementation of bispecific antibodies incorporated into RRMM management. They will describe the major toxicities associated with bispecific antibodies targeting BCMA and GPRC5, including CRS, ICANS, and infection; how they work within their institutions to reduce the risk of these adverse events from occurring; and their experience with monitoring for and treating these adverse events when they arise.
• 
  Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies 22.07.2026 28min

  With updates from the 2026 ASCO Annual Conference signaling long-awaited progress in pancreatic cancer, expert faculty review and discuss recent advances that may influence therapeutic decision-making in a historically chemotherapy-centered field. They examine the current role and limitations of multiagent chemotherapy, the growing importance of early germline and somatic testing, and emerging data for RAS-targeted therapies, including pan-RAS inhibition and allele-specific approaches. Faculty also discuss how molecular subsets such as KRAS wild-type disease, NRG1 fusions, CLDN18.2 expression, MTAP loss, and other actionable alterations may shape future treatment selection, sequencing, clinical trial enrollment, and supportive care planning for patients with pancreatic cancer.
• 
  Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today 14.07.2026 26min

  Targeted therapies are becoming more common treatment options for patients with multiple myeloma. Specifically, there have been emerging clinical data on GPRC5D-directed bispecific antibodies for patients with relapsed and refractory disease. In this podcast, 2 experts in the field discuss how they are using GPRC5D-directed therapies in their practice, including treatment planning, patient selection, adverse event management, and how new combination strategies may affect practice.
• 
  What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma 13.07.2026 28min

  This podcast includes a discussion on what oncology pharmacists need to know about the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy.